JPRN-UMIN000040736已完成未知
A randomized, placebo, double-blind study on improving suppression of fat accumulation in healthy humans by test food - A randomized, placebo, double-blind study on improving suppression of fat accumulation in healthy humans by test food
itta Gelatin Inc. R&D center0 个研究点目标入组 75 人开始时间: 2021年12月30日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. A person with a history of serious illness. 2. Those who have abnormal liver and renal function test values in the health examination. 3. Those who have impaired cardiopulmonary function. 4. People with food and drug allergies. 5. Those who have undergone gastrointestinal surgery. 6. A person who has a chronic or acute infectious disease at the discretion of the doctor. 7. Those who are participating in other clinical studies at the start of this study. 8. Those who play intense sports and those on a diet. 9. Pregnant person. 10. Any other person who is judged to be inappropriate by the person in charge of the examination or the person in charge of the examination.
研究者
相似试验
进行中（未招募）
4 期
SPL7013 Nasal Spray safety and performance in patients with COVID-19ISRCTN70449927Starpharma (Australia)231
已完成
1 期
A randomized, double-blind, placebo-controlled investigation of the safety, tolerability and pharmacokinetics of 1% SPL7013 nasal spray in healthy volunteers when administered four times a day for 14 daysCOVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12620001371987Starpharma Pty Ltd40
进行中（未招募）
不适用
A randomized doble-blind placebo-controlled study to assess the safety in a one-year of orally administered microencapsulated ragweed pollen extractEUCTR2007-004538-18-HUCuralogic A/S200
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticaria - oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticariaChronic Idiopathic UrticariaEUCTR2005-002749-38-BEBarrier Therapeutics nv48
已完成
2 期
A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticariaChronic urticaria10002426NL-OMON30213Barrier Therapeutics16